Sign In
Buy NVO
$47.42
+1.52 (+3.31%)
At Close: Jun 23, 2026
Novo Nordisk A/S $NVO Shares Sold by Ritholtz Wealth Management
06:10am, Monday, 13'th Apr 2026
Ritholtz Wealth Management reduced its holdings in Novo Nordisk A/S (NYSE: NVO) by 19.7% in the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commission (
Clear Creek Financial Management LLC Acquires Shares of 16,138 Novo Nordisk A/S $NVO
04:00am, Monday, 13'th Apr 2026
Clear Creek Financial Management LLC acquired a new position in shares of Novo Nordisk A/S (NYSE: NVO) in the undefined quarter, according to its most recent disclosure with the SEC. The fund acquired
LLY v. NVO: Weighing Who's Winning the GLP-1 Industry
09:30am, Sunday, 12'th Apr 2026
Scott Zari returns to the Watch List and offers the latest updates around the GLP-1 trade and the two companies leading it: Eli Lilly (LLY) and Novo Nordisk (NVO). He sees weight loss drug efficacy be
Carnegie Investment Counsel Sells 27,820 Shares of Novo Nordisk A/S $NVO
04:19am, Saturday, 11'th Apr 2026
Carnegie Investment Counsel lessened its holdings in shares of Novo Nordisk A/S (NYSE: NVO) by 10.2% during the fourth quarter, according to the company in its most recent filing with the Securities a
Genetic variations linked to weight loss, side effects from GLP-1 drugs
04:07pm, Friday, 10'th Apr 2026
Weight-loss responses to GLP-1 obesity drugs, and risks of side effects, may be linked to genetic variants, according to a study conducted by DNA-testing service 23AndMe.
Eli Lilly vs. Novo Nordisk: The Obesity Drug Race Has a New Leader
12:09pm, Friday, 10'th Apr 2026
Eli Lilly and Company (NYSE:LLY | LLY Price Prediction) and Novo Nordisk A/S (NYSE:NVO) reported quarterly results in early February, and the gap between them has widened significantly.
Novo Nordisk's GLP-1 pill momentum faces pricing test, says leading bank
12:08pm, Friday, 10'th Apr 2026
Novo Nordisk (NYSE:NVO) reports first-quarter 2026 results on 6 May, with UBS flagging that the results will provide the first meaningful look at the...
Novo Nordisk's GLP-1 pill momentum faces pricing test, says leading bank
11:19am, Friday, 10'th Apr 2026
Novo Nordisk (NYSE:NVO) reports first-quarter 2026 results on 6 May, with UBS flagging that the results will provide the first meaningful look at the company's economics at new, lower price points for
Novo Nordisk A/S (NVO) Is a Trending Stock: Facts to Know Before Betting on It
10:01am, Friday, 10'th Apr 2026
Recently, Zacks.com users have been paying close attention to Novo Nordisk (NVO). This makes it worthwhile to examine what the stock has in store.
Stock Market Today (LIVE): Court Greenlights Meta Addiction Suit; TSMC Revenue Hits Record High
09:50am, Friday, 10'th Apr 2026
Top insights from the latest market news from Friday, April 10, from The Motley Fool analysts on Team Rule Breakers and Team Hidden Gems.
Is NVO Undervalued? DCF Says Worth $88
07:56am, Friday, 10'th Apr 2026
On April 10, 2026, we present a DCF analysis for Novo Nordisk AS (NVO), a company currently facing significant price performance challenges, with a year-to-date
Bfsg LLC Cuts Stock Position in Novo Nordisk A/S $NVO
03:29am, Friday, 10'th Apr 2026
Bfsg LLC decreased its stake in shares of Novo Nordisk A/S (NYSE: NVO) by 60.2% during the undefined quarter, according to the company in its most recent filing with the Securities and Exchange Commis
Eli Lilly market share drops, Novo Nordisk holds firm as generic weight-loss drugs flood India
02:38am, Friday, 10'th Apr 2026
Eli Lilly's market share in India's weight‑loss drug market fell to 56% in March from 61% in February. Novo Nordisk's market share remained steady at 25%.
Novo Nordisk's weight loss pill is drawing in new patients for obesity treatment
03:30pm, Thursday, 09'th Apr 2026
Novo Nordisk's new Wegovy GLP-1 pill appears to be expanding the obesity treatment market, drawing in new patients rather than converting existing ones from injections. CNBC's Annika Kim Constantino e
Wall Street Breakfast Podcast: STAAR Prelims Signal Upside
07:09am, Thursday, 09'th Apr 2026
STAAR Surgical (STAA) expects Q1 net sales to exceed $90M, more than doubling year-over-year, driven primarily by China and double-digit growth in the Americas. Disney plans 1,000 job cuts in marketin
